Employees: 11-50
Total raised: $11M
Founded date: 2012
Investors 2
| Date | Name | Website |
| - | Vincero | vinceroinv... |
| - | Elysia Cap... | elysiacapi... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.08.2019 | Series A | $11M | - |
Mentions in press and media 8
| Date | Title | Description |
| 04.08.2021 | Chardan Healthcare Acquisition 2 : Announces Record Date for Stockholders Eligible to Vote on Merger (Form 8-K) | Chardan Healthcare Acquisition 2 Corp. Announces Record Date for Stockholders Eligible to Vote on Merger PHILADELPHIA and NEW YORK, August 3, 2021- Chardan Healthcare Acquisition 2 Corp. (the 'Company') announced that the close of business ... |
| 03.08.2021 | Chardan Healthcare Acquisition 2 : Announces Record Date for Stockholders Eligible to Vote on Merger | PHILADELPHIA and NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Chardan Healthcare Acquisition 2 Corp. (the "Company") announced that the close of business on Thursday, August 5, 2021, has been set as the record date for the determination... |
| 23.03.2021 | Renovacor, Inc. : to Merge with Chardan Healthcare Acquisition 2 Corp. | PHILADELPHIA and NEW YORK, March 23, 2021 /PRNewswire/ -- Renovacor, Inc. ("Renovacor" or the "Company"), an early-stage biotechnology company developing AAV-based gene therapies for devastating cardiovascular and centra... |
| 23.03.2021 | CHARDAN HEALTHCARE ACQUISITION 2 CORP. Renovacor, Inc. : to Merge with Chardan Healthcare Acquisition 2 Corp. | PHILADELPHIA and NEW YORK, March 23, 2021 /PRNewswire/ -- Renovacor, Inc. ("Renovacor" or the "Company"), an early-stage biotechnology company developing AAV-based gene therapies for devastating cardiovascular and centra... |
| 24.02.2020 | Anne Prener, M.D., Ph.D. Appointed to Renovacor Board of Directors and Scientific Advisory Board | Former CEO of Freeline Therapeutics, Ltd. has outstanding international drug development, commercialization expertise, with focus on rare disease, gene therapy PHILADELPHIA–(BUSINESS WIRE)–February 24, 2020– Renovacor, Inc, a preclinical-st... |
| 15.08.2019 | Daily funding roundup - August 15th, 2019 | Miko raised $7.5M; Commsignia closed $11M; FlyHomes landed $21M; Nurx secured $32M Fitz Frames: Fitz Frames is solving glasses for kids and parents because those who can see the world are the ones who will change it. Fitz Frames has raised ... |
| 14.08.2019 | Renovacor Closes $11 Million Series A Financing to Advance First Gene Therapy for a Rare Cardiovascular Disease | – Funding supports preclinical development through IND submission for its BAG3 gene therapy, the first gene replacement product for genetic forms of dilated cardiomyopathy – Company announces leadership team and board of directors with lead... |
| 14.08.2019 | Renovacor Completes $11M Series A Financing Round | Magdalene Cook, MD, President and CEO of Renovacor Renovacor, Inc., a Philadelphia, PA-based preclinical-stage biopharmaceutical company focused on developing gene therapy-based treatments for cardiovascular disease, closed an $11m Series A... |